Patients with nonsquamous
non-small cell lung cancer (nsNSCLC; largely
lung adenocarcinoma) are at high risk of developing
brain metastases. Preclinical data suggested that anti-
VEGF-A therapy may prevent the formation of nsNSCLC
brain metastases. Whether non-
brain metastases are also prevented, and whether
bevacizumab shows a
brain metastases-preventive activity in
cancer patients is unknown. Data of one nsNSCLC (stage IIIB/IV, AVAiL) and two
breast cancer bevacizumab trials (HER2 negative, AVADO; HER2 positive, AVEREL) were retrospectively analyzed regarding the frequency of the brain versus other organs being the site of first relapse. For animal studies, the outgrowth of PC14-PE6
lung adenocarcinoma cells to brain macrometastases in mice was measured by intravital imaging: under control
IgG (25 mg/kg) treatment, or varying doses of
bevacizumab (25 mg/kg, 2.5 mg/kg, 0.25 mg/kg).
Brain metastases as site of first relapse were significantly less frequent in the
bevacizumab arm of the AVAiL trial (HR = 0.36, P < 0.001). In AVADO and AVEREL, no significant difference was seen. In mice,
bevacizumab treatment led to secondary regressions of non-brain macrometastases, but did not reduce their total incidence, and did not improve survival. In a brain-seeking nsNSCLC
metastasis model, treatment with
bevacizumab inhibited
brain metastases formation, which resulted in improved overall survival. In summary,
bevacizumab has the potential to prevent
brain metastases in nsNSCLC, but no preventive activity could be detected outside the brain. These data indicate that anti-
VEGF-A agents might be particularly relevant for those stage III nsNSCLC patients who are at high risk to develop future
brain metastases. Mol
Cancer Ther; 15(4); 702-10. ©2016 AACR.